Literature DB >> 25491909

Recurrent severe acute hepatitis caused by hypereosinophilic syndrome associated with elevated serum immunoglobulin G4 levels.

Tomonori Aoyama1, Toshiharu Matsumoto, Akira Uchiyama, Kazuyoshi Kon, Shunhei Yamashina, Satoko Suzuki, Kenichi Ikejima, Takashi Yao, Ryohei Kuwatsuru, Sumio Watanabe.   

Abstract

A 46-year-old male was admitted to our hospital with severe acute hepatitis, hypereosinophilia, and serum immunoglobulin G4 (IgG4) elevation. Plasma exchange was performed, and he was treated by prednisolone; however, his hepatitis recurred twice over the following twelve months. Transjuglar liver biopsy was performed at the third onset, which demonstrated extensive hepatocyte necrosis, congestion, and severe eosinophil infiltration. We diagnosed hypereosinophilic syndrome (HES)-related hepatitis. Although no cholangitis was detected by imaging and pathological diagnosis, IgG4-positive cells were detected in the liver and bone marrow. Furthermore, the elevation of serum IgG4 levels was associated with the eosinophil count and his clinical condition. After the addition of azathioprine to his treatment regimen, no reoccurrence was observed. IgG4-positive cells may have contributed to the severity and refractoriness of this recurrent acute HES-related hepatitis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25491909     DOI: 10.1007/s12328-014-0532-0

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  19 in total

1.  Eosinophil-induced chronic active hepatitis in the idiopathic hypereosinophilic syndrome.

Authors:  A Foong; J V Scholes; G J Gleich; G M Kephart; P R Holt
Journal:  Hepatology       Date:  1991-06       Impact factor: 17.425

Review 2.  Consensus statement on the pathology of IgG4-related disease.

Authors:  Vikram Deshpande; Yoh Zen; John Kc Chan; Eunhee E Yi; Yasuharu Sato; Tadashi Yoshino; Günter Klöppel; J Godfrey Heathcote; Arezou Khosroshahi; Judith A Ferry; Rob C Aalberse; Donald B Bloch; William R Brugge; Adrian C Bateman; Mollie N Carruthers; Suresh T Chari; Wah Cheuk; Lynn D Cornell; Carlos Fernandez-Del Castillo; David G Forcione; Daniel L Hamilos; Terumi Kamisawa; Satomi Kasashima; Shigeyuki Kawa; Mitsuhiro Kawano; Gregory Y Lauwers; Yasufumi Masaki; Yasuni Nakanuma; Kenji Notohara; Kazuichi Okazaki; Ji Kon Ryu; Takako Saeki; Dushyant V Sahani; Thomas C Smyrk; James R Stone; Masayuki Takahira; George J Webster; Motohisa Yamamoto; Giuseppe Zamboni; Hisanori Umehara; John H Stone
Journal:  Mod Pathol       Date:  2012-05-18       Impact factor: 7.842

Review 3.  IgG4-related disease.

Authors:  Vinay S Mahajan; Hamid Mattoo; Vikram Deshpande; Shiv S Pillai; John H Stone
Journal:  Annu Rev Pathol       Date:  2013-10-02       Impact factor: 23.472

Review 4.  Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis.

Authors:  J H Butterfield
Journal:  Acta Haematol       Date:  2005       Impact factor: 2.195

5.  Clinical features of fifteen patients with the hypereosinophilic syndrome.

Authors:  C J Spry; J Davies; P C Tai; E G Olsen; C M Oakley; J F Goodwin
Journal:  Q J Med       Date:  1983

6.  Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes.

Authors:  Peter Valent; Amy D Klion; Hans-Peter Horny; Florence Roufosse; Jason Gotlib; Peter F Weller; Andrzej Hellmann; Georgia Metzgeroth; Kristin M Leiferman; Michel Arock; Joseph H Butterfield; Wolfgang R Sperr; Karl Sotlar; Peter Vandenberghe; Torsten Haferlach; Hans-Uwe Simon; Andreas Reiter; Gerald J Gleich
Journal:  J Allergy Clin Immunol       Date:  2012-03-28       Impact factor: 10.793

Review 7.  Eosinophilic hepatic necrosis in hypereosinophilic syndrome.

Authors:  K A Ung; H Remotti; R Olsson
Journal:  J Clin Gastroenterol       Date:  2000-12       Impact factor: 3.062

8.  Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.

Authors:  Georgia Metzgeroth; Christoph Walz; Philipp Erben; Helena Popp; Annette Schmitt-Graeff; Claudia Haferlach; Alice Fabarius; Susanne Schnittger; David Grimwade; Nicholas C P Cross; Rüdiger Hehlmann; Andreas Hochhaus; Andreas Reiter
Journal:  Br J Haematol       Date:  2008-10-17       Impact factor: 6.998

9.  The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.

Authors:  Michele Baccarani; Daniela Cilloni; Michela Rondoni; Emanuela Ottaviani; Francesca Messa; Serena Merante; Mario Tiribelli; Francesco Buccisano; Nicoletta Testoni; Enrico Gottardi; Antonio de Vivo; Emilia Giugliano; Ilaria Iacobucci; Stefania Paolini; Simona Soverini; Gianantonio Rosti; Francesca Rancati; Cinzia Astolfi; Fabrizio Pane; Giuseppe Saglio; Giovanni Martinelli
Journal:  Haematologica       Date:  2007-08-01       Impact factor: 9.941

Review 10.  Current concept and diagnosis of IgG4-related disease in the hepato-bilio-pancreatic system.

Authors:  Kazuichi Okazaki; Kazushige Uchida; Tsukasa Ikeura; Makoto Takaoka
Journal:  J Gastroenterol       Date:  2013-02-16       Impact factor: 7.527

View more
  4 in total

1.  Idiopathic hypereosinophilic syndrome presenting with hepatitis and achalasia.

Authors:  Amanda C Cheung; Christine Y Hachem; Jinping Lai
Journal:  Clin J Gastroenterol       Date:  2016-06-13

2.  Gastrointestinal and Hepatic Involvement in Hypereosinophilic Syndrome.

Authors:  Faisal Inayat; Abu Hurairah
Journal:  Cureus       Date:  2016-08-31

3.  Acute Liver Failure Due to Hypereosinophilic Syndrome Accompanied by Duodenal Perforation.

Authors:  Shuichi Tange; Koji Uchino; Hirotoshi Kakiwaki; Hirobumi Suzuki; Shinzo Yamamoto; Yukiko Ito; Hiroyoshi Taniguchi; Harumi Shirai; Takeshi Suzuki; Haruna Onoyama; Sakae Nagaoka; Toshio Kumasaka; Hideo Yoshida
Journal:  Intern Med       Date:  2021-10-19       Impact factor: 1.282

4.  Concurrent eosinophilia and IgG4-related disease in a child: A case report and review of the literature.

Authors:  Can Chen; Kuang Chen; Xilian Huang; Kaile Wang; Shenxian Qian
Journal:  Exp Ther Med       Date:  2018-01-12       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.